Tildacerfont-d₈  (Synonyms: SPR001-d₈; LY2371712-d₈)

Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

428.02

C₂₀H₁₈D₈ClN₅OS

2762751-36-8

1014983-00-6

CC1=NN(C(C(CC)CC)=CC(C)=N2)C2=C1C3=C(Cl)N=C(N4C([2H])([2H])C([2H])([2H])OC([2H])([2H])C4([2H])[2H])S3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Prete A, et al. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186(1):R1-R14. Published 2021 Nov 30.   [Content Brief]